SUVpeak Performance in Lung Cancer: Comparison to Average SUV from the 40 Hottest Voxels.
Journal of Nuclear Medicine. 2015-11-12; 57(1): 85-88
DOI: 10.2967/jnumed.115.161968
Lire sur PubMed
1. J Nucl Med. 2016 Jan;57(1):85-8. doi: 10.2967/jnumed.115.161968. Epub 2015 Nov
12.
SUVpeak Performance in Lung Cancer: Comparison to Average SUV from the 40 Hottest
Voxels.
Laffon E(1), Burger IA(2), Lamare F(3), de Clermont H(3), Marthan R(4).
Author information:
(1)CHU de Bordeaux, Service de Médecine Nucléaire, Pessac, France Université de
Bordeaux 2, Centre de Recherche Cardio-Thoracique, Bordeaux, France INSERM U
1045, Centre de Recherche Cardio-Thoracique, Bordeaux, France; and
.
(2)Division of Nuclear Medicine, Department of Medical Radiology, University
Hospital of Zurich, Zurich, Switzerland.
(3)CHU de Bordeaux, Service de Médecine Nucléaire, Pessac, France.
(4)Université de Bordeaux 2, Centre de Recherche Cardio-Thoracique, Bordeaux,
France INSERM U 1045, Centre de Recherche Cardio-Thoracique, Bordeaux, France;
and.
The performance of an average SUV over a 1-mL-volume sphere within an
(18)F-FDG-positive lesion resulting in the highest possible value (SUVpeakW) was
compared with that of an average SUV computed from the 40 hottest voxels,
irrespective of their location within the lesion (SUVmax-40).METHODS: Dynamic PET
performed in 20 lung cancer lesions yielded for each SUV metric its mean value,
relative measurement error, and repeatability (MEr-R).
RESULTS: SUVpeakW mean value was significantly 9.66% lower than that of SUVmax-40
(P < 0.0001). SUVpeakW and SUVmax-40 MEr-R were significantly lower than the
MEr-R of SUVmax (the hottest voxel): 9.35%-13.21% and 8.84%-12.49% versus
13.86%-19.59%, respectively, (95% confidence limit; P < 0.0001). Although being
marginal, SUVpeakW MEr-R was not significantly greater than SUVmax-40 MEr-R (P =
0.086).
CONCLUSION: SUVmax-40 is more likely to represent the most metabolically active
portions of tumors than SUVpeakW, with close variability performance.
© 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
DOI: 10.2967/jnumed.115.161968
PMID: 26564325 [Indexed for MEDLINE]